Did Ascendis Pharma beat or miss consensus estimates last quarter?

What were the key takeaways from Ascendis Pharma’s earnings call?

What factors drove the changes in Ascendis Pharma's revenue and profit?

What does Ascendis Pharma do and what are its main business segments?

What were the key takeaways from Ascendis Pharma's earnings call?

What is the revenue and EPS growth rate for Ascendis Pharma year over year?

What is Ascendis Pharma's latest dividend and current dividend yield?

What is the market's earnings forecast for Ascendis Pharma next quarter?

- **YORVIPATH Growth**: €143.1M Q3 revenue, 4,250+ U.S. patients, 70% approval rate, Japan launch, and 30+ European markets.
- **SKYTROFA Expansion**: AGHD approval, €50.7M Q3 revenue, Phase III trial for additional growth disorders.
- **TransCon CNP Update**: FDA PDUFA date November 30, 2025; Phase II combo trial shows 3x linear growth, Phase III planned for Q4 2025.
- **Financial Health**: €214M total revenue, €11M operating profit, €539M cash, and 9% cash growth.

**【CEO Summary Section】**
- **YORVIPATH Global Launch Momentum**: Q3 revenue of €143.1 million, with over 4,250 U.S. patients prescribed and 2,000 unique prescribers. Japan launched commercially in August, and Europe expanded to 30+ countries. U.S. approval rate for new patients is ~70%, expected to improve over time.
- **SKYTROFA Expansion**: U.S. approval for adult growth hormone deficiency (AGHD) in July, Q3 revenue €50.7 million. Phase III basket trial initiated for additional growth disorders (ISS, SHOX deficiency, Turner syndrome).
- **TransCon CNP Regulatory Progress**: FDA priority review with PDUFA date November 30, 2025. Phase II COACH trial shows 3x linear growth in achondroplasia when combined with TransCon GH, with plans for Phase III trial in Q4 2025.

**【CFO Financial Commentary】**
- **Q3 2025 Financials**: Total revenue €214 million (YORVIPATH: €143.1M, SKYTROFA: €50.7M, collaboration: €20M). Operating profit €11 million (vs. loss €12.5M in Q3 2024). Cash balance €539 million, up 9% from Q2 2025.
- **Expense Management**: R&D expenses down 9% to €66.9 million, SG&A up 63% to €113.4 million due to global commercial expansion.

**【Q&A Highlights】**
- **Patient Retention**: >95% of patients stay on YORVIPATH after 4-6 weeks, driven by once-weekly dosing and stable calcium management.
- **TransCon CNP Labeling**: FDA in late-stage discussions, with focus on linear growth and safety (no hypotension, low injection site reactions). Phase III trial design expected to align with 1-year data requirement.
- **International Expansion**: Japan launch underway, Europe targeting 30+ countries, and U.S. SKYTROFA label expansion for AGHD.

Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript

- **YORVIPATH Breakout**: Q2 revenue doubles to EUR 103M, 3,100 U.S. patients enrolled. 70%+ patients approved within 3 months. 
- **CNP Leadership**: FDA priority review for achondroplasia; combo trial shows 3x growth velocity vs. monotherapy. 
- **Cash Flow Positive**: EUR 494M cash, expecting quarterly cash breakeven. 
- **Blockbuster Potential**: YORVIPATH targeting >EUR 2B peak; TransCon CNP combo therapy Phase III Q4. 


**【CEO Summary Section】**
- **YORVIPATH Performance**: Q2 revenue EUR 103M (double Q1), 1,500 U.S. prescribers, 3,100 patients. Europe Direct and international markets growing; Japan approval expected Q3. 
- **TransCon CNP Milestones**: FDA priority review for achondroplasia; combination trial with TransCon GH shows 3x growth velocity vs. monotherapy. Phase III combo trial planned Q4. 
- **SKYTROFA Expansion**: FDA approval for adult GHD; Phase III trials for ISS, Turner syndrome. 
- **Long-Term Vision**: Multiple blockbusters (YORVIPATH, TransCon CNP) targeting EUR 5-8B market for hypoparathyroidism. 

**【CFO Financial Commentary】**
- **Q2 Financials**: Total revenue EUR 153.7M (YORVIPATH 67%, SKYTROFA 33%). R&D down 14% to EUR 72M, SG&A up 44% to EUR 107.6M. Cash EUR 494M (-EUR 19M sequential). 
- **Key Metrics**: YORVIPATH U.S. prescriptions growing 1,500/month; 70%+ patients approved within 3 months. SKYTROFA adult label to drive long-term growth. 
- **Guidance**: YORVIPATH peak sales potential >EUR 2B; SKYTROFA sequential growth offset by seasonality. 

**【Q&A Key Highlights】**
- **Enrollment Trends**: Stable at 1,500/month in U.S.; 70%+ conversion to therapy. Europe Direct launches in Spain, Germany, Austria. 
- **TransCon CNP Differentiation**: Only CNP with once-weekly dosing, no hypertension risk. Combination therapy shows superior growth velocity. 
- **Financial Modeling**: YORVIPATH U.S. 2025: 15,000-20,000 patients; Europe Direct 2025: 10-15% growth. SG&A ~EUR 190M/quarter. 
- **Regulatory Strategy**: 60mcg YORVIPATH trial underway; combo therapy Phase III planned Q4. 


Ascendis Pharma A/S (ASND)-7 Aug 25-2025 Q2 Earnings call transcript

- **YORVIPATH U.S. Dominance**: €44.7M Q1 revenue, 1,750+ patients, 1,000+ prescribers. 4-8 week reimbursement approvals, 17-18% steady-state utilization projected.
- **SKYTROFA Expansion**: 7% U.S. growth hormone market share, adult indication PDUFA July 27, 2025. Basket trial for idiopathic short stature, Turner syndrome.
- **TransCon CNP Breakthrough**: 5.6 cm linear growth in ApproaCH Trial, leg bowing improvement, Q3 2025 MAA filing. COACH trial combo with growth hormone targeting Q2 2025 data.
- **Pipeline Ambition**: YORVIPATH + growth hormone combo for hypoparathyroidism (IND Q4 2025). Novo Nordisk collaboration for metabolic disease applications.
- **Financial Strength**: €518M cash, YORVIPATH driving 2025 growth. Q2 seasonal headwinds reversing, Euro/dollar exchange rate monitoring.

**【CEO Summary Section】**
- **YORVIPATH U.S. Launch Momentum**: Q1 2025 revenue €44.7M, up 235% YoY, with 1,750+ patients prescribed by 1,000+ prescribers. U.S. reimbursement approvals achieved in 4-8 weeks, with high approval rates across commercial and government plans.
- **SKYTROFA Market Position**: Q1 revenue €51.3M, maintaining ~7% U.S. growth hormone market share. Potential label expansion for adult growth hormone deficiency (PDUFA date July 27, 2025) and basket trial for additional indications.
- **TransCon CNP Regulatory Progress**: NDA filed in March 2025, MAA expected Q3 2025. Phase 2 COACH trial combining CNP with growth hormone targeting 26-week data release. Pivotal ApproaCH Trial showed 5.6 cm linear growth vs. placebo, with benefits in leg bowing, muscle function, and quality of life.
- **Pipeline Expansion**: Exploring TransCon CNP + growth hormone combination for hypoparathyroidism (IND submission planned Q4 2025). Collaboration with Novo Nordisk for metabolic disease applications.

**【CFO Financial Commentary】**
- **Q1 2025 Financials**: Total revenue €101M (includes non-product collaboration revenue). YORVIPATH drove €44.7M, SKYTROFA €51.3M. Operating expenses €188M, up 73% YoY due to commercial expansion and R&D costs.
- **Cash Position**: €518M as of March 31, 2025. Expect YORVIPATH to be key growth driver, with U.S. launch momentum and ex-U.S. reimbursement expansion.
- **Q2 Outlook**: Seasonal U.S. growth hormone headwinds reversing, YORVIPATH U.S. demand sustained. Monitoring Euro/dollar exchange rate impact on reported revenue.

**【Q&A Key Highlights】**
- **Reimbursement Dynamics**: Anticipate ~17-18% of U.S. patients ultimately reimbursed at steady state. Channel inventory stable at 1-2 weeks. Gross-to-net expectations align with rare disease precedent.
- **Patient Demographics**: ~80% of U.S. YORVIPATH patients post-surgical, 20% genetic/hormonal etiologies. Adherence rates >99%, similar to clinical trial performance.
- **Competitor Analysis**: Calcilytics (e.g., MPX-001) targeting ADH1 (n=350 U.S. patients), MPX-002 weekly PTH analog lacks efficacy vs. YORVIPATH. TransCon technology superior for chronic PTH delivery.
- **TransCon CNP Combination**: COACH trial evaluating CNP + growth hormone for enhanced linear growth and complication mitigation. Potential to address unmet needs in achondroplasia beyond height.

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

- **YORVIPATH Breakthrough**: 908 U.S. prescriptions in 8 weeks, 80% new patients switching from conventional therapy. Global potential with 70K-90K U.S. patients. 
- **SKYTROFA Growth**: €200M 2024 revenue, 37% Q4 volume growth. Adult indication PDUFA date July 2025. 
- **Pipeline Expansion**: TransCon CNP NDA in Q1 2025, $100M upfront from Novo Nordisk for metabolic programs. 
- **Financial Strength**: €665M cash post-Novo payment, targeting 2025 cash breakeven. 


**【CEO Key Highlights】**
- **SKYTROFA Momentum**: Achieved €200M revenue in 2024 with 6.5% U.S. market share, targeting adult growth hormone deficiency (PDUFA date: July 27, 2025). Q4 volume grew 37% YoY, driven by premium pricing (3x daily GH). 
- **YORVIPATH Launch Success**: 908 U.S. prescriptions within 8 weeks, 80% new patients switching from conventional therapy. Global potential with 70K-90K U.S. patients and multi-billion-dollar opportunity. 
- **TransCon CNP Pipeline**: NDA submission for achondroplasia in Q1 2025, MAA in Q3 2025. Phase 2 combo trial with TransCon GH expected Q2 2025. 
- **Strategic Expansion**: $100M upfront from Novo Nordisk for metabolic programs, expanding TransCon platform to oncology (IL-2 β/γ) and ophthalmology (Eyconis). 

**【CFO Financial Summary】**
- **Q4 2024 Results**: Total revenue €173.9M (including $100M Novo payment). SKYTROFA revenue €58.5M (+37% YoY), YORVIPATH €13.6M. 
- **Expenses**: R&D €79.3M (-13% YoY), SG&A €80.2M (+25% YoY) due to commercial expansion. Full-year cash €655M post-Novo payment. 
- **2025 Outlook**: YORVIPATH to drive growth, targeting cash breakeven with €665M balance sheet. 

**【Q&A Key Takeaways】**
- **YORVIPATH Reimbursement**: 35 states with approved shipments, 4-8 week approval timeline. 20% of prescriptions from EAP/clinical trial rollover, 80% new patients. 
- **SKYTROFA Adult Market**: <5% penetration, 100K+ U.S. adults with deficiency. Once-weekly convenience vs. daily GH. 
- **TransCon CNP Combo**: Phase 2 data expected Q2 2025, targeting superior linear growth in achondroplasia. 
- **Supply Chain**: Robust manufacturing to meet demand, no shortages anticipated. 


ASND

ASND fundamentals

Earnings Call

You can ask Aime